This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Basic classification information | |
|---|---|
| ICD-10 | E76.2 |
| Special Copayment Reduction code | V117 |
| Main Korean name | Sanfilippo syndrome (mucopolysaccharidosis type III) |
| Synonyms | Sanfilippo (type B)(type C)(type D) syndrome, mucopolysaccharidosis type III, MPS III, MPS IIIA, MPS IIIB, MPS IIIC, MPS IIID |
| 1. History | 2. Causes |
| 3. Genetics | 4. General epidemiology |
| 5. Pathophysiology | 6. Symptoms |
| 7. Signs | 8. Screening |
| 9. Diagnosis | 10. Treatment |
| 11. Prognosis | 12. Prevention |
| 13. References | |
Mucopolysaccharidosis type III (MPS III), i.e., Sanfilippo syndrome, was first described as an independent disease entity in 1963 by the American pediatrician Sylvester J. Sanfilippo. Sanfilippo and colleagues found increased urinary excretion of heparan sulfate in a group of pediatric patients who showed severe intellectual disability and behavioral problems but relatively mild skeletal abnormalities, and reported it as a new clinical category distinct from the other existing MPS types.
Over more than 10 years of subsequent research, it was shown that MPS III, which appears clinically uniform, actually consists of 4 subtypes caused by different enzyme deficiencies. In 1972, Kresse and Neufeld identified deficiency of heparan-N-sulfatase as the causative enzyme of MPS IIIA; in 1973, deficiency of alpha-N-acetylglucosaminidase (NAGLU), the cause of MPS IIIB; in 1976, deficiency of acetyl-CoA:alpha-glucosaminide acetyltransferase (HGSNAT) in MPS IIIC; and in 1980, deficiency of N-acetylglucosamine-6-sulfatase (GNS) in MPS IIID. In the era of molecular genetics, the causative genes of each subtype (SGSH, NAGLU, HGSNAT, GNS) were cloned, making genotype-phenotype correlation studies possible.
To date, there is no specifically approved treatment for MPS III, but numerous clinical trials of gene therapy, substrate reduction therapy, and enzyme replacement therapy are in progress.
MPS III is caused by deficiency of one of 4 lysosomal enzymes needed for the degradation of heparan sulfate, and the deficient enzyme and causative gene differ by subtype.
| Subtype | Deficient enzyme | Causative gene | Chromosomal location |
|---|---|---|---|
| MPS IIIA | Heparan-N-sulfatase | SGSH | 17q25.3 |
| MPS IIIB | Alpha-N-acetylglucosaminidase (NAGLU) | NAGLU | 17q21.2 |
| MPS IIIC | Acetyl-CoA:alpha-glucosaminide acetyltransferase (HGSNAT) | HGSNAT | 8p11.21 |
| MPS IIID | N-acetylglucosamine-6-sulfatase (GNS) | GNS | 12q14.3 |
All four subtypes are deficiencies of enzymes that catalyze different, consecutive steps in the stepwise lysosomal degradation of heparan sulfate, and undegraded heparan sulfate fragments accumulate within lysosomes. All subtypes are inherited in an autosomal recessive manner.
Numerous pathogenic variants have been reported in the causative gene of each subtype. More than 200 variants are known in the SGSH gene and more than 180 in the NAGLU gene. Variants in the HGSNAT and GNS genes are fewer, but various pathogenic variants have also been identified. Missense mutations are the most common, and in some regions certain founder mutations have a high frequency.
In MPS IIIA, the p.R74C, p.S66W, and p.R245H variants are frequently reported in Europe, and p.R245H in particular is associated with a mild phenotype. In MPS IIIB, p.R297X and p.E153K are recurrently reported. Within each subtype, there is a genotype-phenotype correlation in which clinical severity varies with the level of residual enzyme activity, but its predictive power is not complete.
Because the mode of inheritance is autosomal recessive in all subtypes, the sibling recurrence risk is 25%. Prenatal diagnosis is possible via CVS or amniocentesis by enzyme activity measurement or molecular genetic methods. Differential diagnosis of subtypes is possible with a multiplexed enzyme assay or next-generation sequencing (NGS)-based gene panel testing.
MPS III is the most common type of MPS, accounting for more than about 50% of all MPS. The worldwide incidence is estimated at about 1–4 per 100,000 births. A Dutch study reported an overall MPS III incidence of about 1.89 per 100,000 births. By subtype, there are regional differences: MPS IIIA is the most common in Europe, MPS IIIB is relatively predominant in Southern Europe and the Middle East, and MPS IIIA in Northern Europe.
There is no sex difference, and it occurs equally in males and females. The age at diagnosis is usually between 2 and 6 years, and patients are often referred for developmental regression or behavioral problems. Because of relatively mild skeletal·somatic symptoms, MPS III is often initially misdiagnosed as autism spectrum disorder, ADHD, delayed language development, etc., so the delay until actual diagnosis can average several years.
Heparan sulfate is widely distributed on the cell surface and in the extracellular matrix as part of proteoglycans and serves various biological functions, such as growth factor signaling, cell adhesion, and regulation of developmental processes. Normal degradation of heparan sulfate within the lysosome requires four sulfatases and glycosidases to act sequentially. In any subtype of MPS III, when one step of this process is blocked, heparan sulfate fragments accumulate within lysosomes.
The effects of heparan sulfate accumulation are particularly prominent in the nervous system. The accumulated heparan sulfate directly impairs lysosomal function and secondarily causes impairment of the autophagy pathway, mitochondrial dysfunction, neuronal lysosomal swelling, and secondary accumulation of GM2·GM3 gangliosides. Neuroinflammation is also an important pathological mechanism, with activation of microglia and astrocytes accelerating neuronal death. In particular, a mechanism by which heparan sulfate fragments induce NMDA receptor-mediated neurotoxicity is also being studied.
In somatic organs, accumulation also occurs in the spleen, liver, kidney, connective tissue, etc., but tends to have less clinical impact than in the nervous system. This relative neurospecificity is the key feature that clinically distinguishes MPS III from other MPS.
MPS III is characterized by a 3-stage clinical course.
Children usually appear normal at birth, and development during the first few months is also normal. From about 1–2 years of age, delayed language development appears first, accompanied by reduced social interaction and poor concentration. Misdiagnosis as autism spectrum disorder or delayed language development is very common during this period.
This is the most characteristic stage, with severe hyperactivity, impulsivity, aggressive behavior, and sleep disturbances being prominent. Behavioral problems in this period cause extreme stress for families and caregivers. Cognitive function shows a plateau or gradual regression, and language ability begins to be lost gradually.
As hyperactivity decreases, progressive neurological regression proceeds. Loss of walking ability, dysphagia, epileptic seizures, etc. appear. Eventually, the patient becomes completely dependent. Sleep disturbances (reversal of the sleep-wake cycle, nighttime insomnia) persist as a serious problem throughout the entire course.
A characteristic of MPS III is that its somatic findings are mild compared with other MPS, which is an important cause of delayed diagnosis.
Relatively mild coarsening of the face may appear, but it is much less prominent than in Hurler syndrome (MPS I) and others. Thick eyebrows, a low nasal bridge, and thick lips are observed in some cases. It is difficult to reach a diagnosis from facial features alone.
Coarse hair, hirsutism, and thick skin are characteristic. These are understood to be due to systemic metabolic abnormalities rather than GAG deposition.
Although milder than in other MPS, findings of mild dysostosis multiplex may be observed radiographically. Joint range of motion is generally normal or mildly limited. Clubfoot (talipes equinovarus) or mild thoracolumbar abnormalities may appear.
Mild to moderate hepatosplenomegaly is observed, but it may not be clinically prominent in some patients. Liver function is generally preserved.
Epileptic seizures are common in the later stages, and muscle tone progresses from hypotonia to spasticity. In the terminal stage, demyelination findings and cerebral atrophy are observed on brain MRI. Hearing loss is also commonly present.
Newborn screening for MPS III has not yet been adopted as a standard clinical tool, but measurement of heparan sulfate biomarkers (heparan sulfate in urine or DBS) by LC-MS/MS is under investigation. A DBS-based multiplexed enzyme assay is also being developed to screen for MPS IIIA and IIIB simultaneously.
The most widely used first-line screening methods are quantitative urinary GAG analysis and electrophoresis. Urinary heparan sulfate is markedly increased in MPS III patients, and a pattern in which mainly heparan sulfate is increased, without an increase in dermatan sulfate or chondroitin sulfate, is a clue that distinguishes it from other MPS. However, the sensitivity of the urinary GAG test is limited, and false negatives can occur.
When there is clinical suspicion—particularly in children with a combination of unexplained behavioral disorder, developmental regression, and sleep disturbance—performing a lysosomal enzyme activity test together with urinary GAG analysis helps reduce diagnostic delay.
MPS III is confirmed by measuring the enzyme activity of the relevant subtype in leukocytes or fibroblasts. Enzyme tests are available for every subtype, and when MPS III is clinically suspected, testing for all four subtypes at the same time is recommended.
Sequencing of the SGSH, NAGLU, HGSNAT, and GNS genes (including NGS panels) is used to identify pathogenic variants. It is essential for confirming the subtype, prognostic counseling, and prenatal diagnosis.
To date there is no approved disease-specific treatment for MPS III, and treatment centers on supportive care aimed at symptom relief and improved quality of life.
AAV-based gene therapy delivered directly to the brain for MPS IIIA (tralesinogene zaparvovec, ABO-102) has been evaluated in clinical trials, and a reduction of heparan sulfate in cerebrospinal fluid has been confirmed. AAV9-based gene therapy for MPS IIIB (LYS-SAF302) is also in clinical trials. Substrate reduction therapy (SRT) research includes molecular chaperone therapy such as arimoclomol. For ERT, because of the difficulty of crossing the blood-brain barrier, direct administration into the cerebrospinal fluid is being studied rather than intravenous administration alone.
MPS III is one of the most severe neurodegenerative MPS to date, and although it varies by subtype and genotype, the overall prognosis is poor. MPS IIIA is the most severe and tends to progress rapidly, with most patients dying in their teens to twenties. MPS IIIB, on average, has a milder course than MPS IIIA, and some patients survive beyond their thirties. MPS IIIC and IIID show more variable rates of progression, and many retain acquired skills for longer.
Causes of death include aspiration pneumonia, heart failure, status epilepticus, and respiratory failure. Mental health support for families and caregivers and collaboration with a multidisciplinary palliative care team are very important elements in the management of MPS III patients. Managing behavioral problems and sleep disturbance caused by progressive neurodegeneration has a key effect on the quality of life of the family.
Primary prevention of MPS III is based on genetic counseling and prenatal diagnosis. Because all subtypes are inherited in an autosomal recessive manner, siblings of a confirmed patient have a 25% recurrence risk. Carrier testing should be performed in both parents, and prenatal diagnosis (enzyme activity measurement or molecular analysis via CVS or amniocentesis) should be offered to at-risk couples.
Preimplantation genetic testing (PGT-M) is also an option when the pathogenic variant in the family has been identified. If newborn screening is introduced, treatment could be started in the asymptomatic neonatal period before neurodegeneration begins, which is expected to improve prognosis substantially. Diagnosis before onset or at an early stage is also essential to obtain the optimal effect of gene therapies currently in development.